XXXX : clinicopathologic features and outcome analysis.

@entity1 @entity1643 @entity440 @entity500 @entity3807 @entity5 @entity3041 @entity288 @entity618 @entity1499 @entity792 @entity1851
To describe clinical features and outcomes of 26 @entity1 with @entity3807 from a single center, we reviewed medical records of consecutive @entity1 with @entity3807 evaluated at our facility from January 1, 1998 to December 31, 2013 for clinical features, laboratory and radiographic findings, management, and outcomes. Twenty-six @entity1 met criteria for @entity3807 and were included in the study. Median age at diagnosis was 58 years; male-female ratio was 3.3:1.0. Median duration of symptoms was 7 weeks. @entity1643 were the most common presenting symptoms. Four @entity1 (15 %) had associated @entity792 . Baseline erythrocyte sedimentation rate was elevated in 17 (77 %) of 22 @entity1 tested and @entity1851 was elevated in 10 (56 %) of 18 @entity1 tested. @entity3041 was present in 17 (68 %) @entity1 ; 8 (47 %) of 17 had bilateral @entity3041 . Retroperitoneal mass biopsy was performed in 18 (69 %) @entity1 . Two @entity1 had @entity3807 classifiable as IgG4-related disease. Therapy consisted of medications alone in 7 cases, surgical interventions alone in 7 cases, and a combination in 11 cases. One @entity1 achieved remission with no treatment. Most @entity1 treated medically received initial @entity288 . @entity1499 (1 case), @entity500 (1 case), @entity618 (1 case), and @entity440 (5 cases) were used. No relapses occurred after a median 5-year follow-up. Two (8 %) @entity1 died; five (19 %) developed @entity5 after diagnosis. In this series, we emphasize the importance of early diagnosis and therapy for overall favorable prognosis of @entity3807 .
